Ivosidenib: First Global Approval
This article summarizes the milestones in the development of ivosidenib leading to this first approval in the USA for the treatment of patients with relapsed or refractory AML with a susceptibleIDH1 mutation. Clinical development for AML, cholangiocarcinoma, glioma, myelodysplastic syndromes and solid tumours is ongoing worldwide.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bile Duct Cancer | Brain Tumor | Cancer | Cancer & Oncology | Cholangiocarcinoma | Drugs & Pharmacology | Glioma | Leukemia | Myelodysplastic Syndrome